Astellas Pharma (ALPMY) Stock Price, News & Analysis

Company Overview

Astellas Pharma Inc. is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation.

The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation. Astellas also develops medicines and investigational therapies through internal research and collaborations with biotechnology and pharmaceutical companies.

Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., two Japanese companies with histories dating back several decades. Headquartered in Tokyo, the company serves markets across North America, Europe, Asia and other regions through a global research, development and commercial organization. Naoki Okamura serves as Astellas Pharma’s president and chief executive officer.

Key Stats

• Today's Range: $14.17 to $14.37
• 50-Day Range: $13.67 to $15.47
• 52-Week Range: $10.03 to $17.35
• Volume: 122,213 shs
• Average Volume: 100,442 shs
• Market Capitalization: $25.97 billion
• P/E Ratio: 10.92
• Dividend Yield: 2.02%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Astellas Pharma Stock Analysis - MarketRank™

Astellas Pharma scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Astellas Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Astellas Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -5.71%

Earnings Growth

Earnings for Astellas Pharma are expected to decrease by -5.71% in the coming year, from $1.40 to $1.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Astellas Pharma is 10.92, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.79.

Price to Earnings Ratio vs. Sector

The P/E ratio of Astellas Pharma is 10.92, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.01.

Price to Book Value per Share Ratio

Astellas Pharma has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Astellas Pharma has been sold short.

Short Interest Ratio / Days to Cover

Astellas Pharma has a short interest ratio ("days to cover") of 0.81, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Astellas Pharma has recently increased by 519.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Astellas Pharma pays a meaningful dividend of 2.02%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Astellas Pharma does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Astellas Pharma is 22.14%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 21.97% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.20

News Sentiment

Astellas Pharma has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Astellas Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Astellas Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Astellas Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/27/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ALPMY
• CIK: 1446390
• Web: www.astellas.com
• Phone: (133) 244-3000
• Fax: N/A
• Employees: 14,099
• Year Founded: 1923

Profitability

• EPS (Trailing Twelve Months): $1.31
• Trailing P/E Ratio: 10.92
• Forward P/E Ratio: 10.25
• P/E Growth: N/A
• Net Income: $1.83 billion
• Net Margins: 16.01%
• Pretax Margin: 17.60%
• Return on Equity: 25.79%
• Return on Assets: 12.87%

Debt

• Debt-to-Equity Ratio: 0.16
• Current Ratio: 1.20
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $14.21 billion
• Price / Sales: 1.83
• Cash Flow: $2.24 per share
• Price / Cash Flow: 6.42
• Book Value: $6.36 per share
• Price / Book: 2.26

Miscellaneous

• Outstanding Shares: 1,809,660,000
• Free Float: N/A
• Market Cap: $25.97 billion
• Optionable: Not Optionable
• Beta: 0.08